Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) Given One Year After Primary Immunization in Healthy Children in South Korea [EXTENSION OF 700202906]

Trial Profile

Immunogenicity and Safety Exploration of a Booster Dose of a Live Attenuated Japanese Encephalitis Chimeric Virus Vaccine (IMOJEV) Given One Year After Primary Immunization in Healthy Children in South Korea [EXTENSION OF 700202906]

Completed
Phase of Trial: Phase III

Latest Information Update: 03 Nov 2015

At a glance

  • Drugs Japanese encephalitis vaccine (Primary)
  • Indications Japanese encephalitis
  • Focus Pharmacodynamics
  • Sponsors sanofi pasteur
  • Most Recent Events

    • 03 Nov 2015 Results published in the Pediatric Infectious Disease Journal
    • 14 Jan 2014 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
    • 25 Jul 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top